Acellena Contract Drug Research and Development   Report issue

For profit Phase 2
Founded: Petersburg Russian Federation (2018)

Organization Overview

First Clinical Trial
2019
NCT04128059
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Acellena Contract Drug Research and Development

Active Ingredients

Drugs in Phase 2 Trials (2)

bvrs-gamvac-combi (1 trial)

gam-covid-vac lyo (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2